Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia

Indian Journal of Critical Care Medicine

Volumn 16, Issue 3, 2012, Pages 141-147

  Fahimi, Fanak ^a   Ghafari, Somayeh ^a   Jamaati, Hamidreza ^a   Baniasadi, Shadi ^a   Tabarsi, Payam ^a   Najafi, Arvin ^a   Akhzarmehr, Arnavaz ^a   Hashemian, Seyed ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Piperacillin; tazobactam; ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; QUASI EXPERIMENTAL STUDY; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84870044614     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.102083     Document Type: Article

References (40)

1. Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilatorassociated pneumonia. Eur J Intern Med 2010;21:360-8. 2.
2. Kollef MH, Schuster DP. Ventilator-associated pneumonia: Clinical considerations. AJR Am J Roentgenol 1994;163:1031-5. 3. (Pubitemid 24355688)
3. Memish ZA, Cunningham G, Oni GA, Djazmati W. The incidence and risk factors of ventilator-associated pneumonia in a Riyadh hospital. Infect Control Hosp Epidemiol 2000;21:271-3. 4.
4. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 11-2.
6. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
7. Vondracek TG. Beta-lactam antibiotics: Is continuous infusion the preferred method of administration? Ann Pharmacother 1995;29:415-24.
8. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000;50:184-91.
9. Pédeboscq S, Dubau B, Frappier S, Hernandez V, Veyssières D, Winnock S, et al. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin]. Pathol Biol (Paris) 2001;49:540-7. 10.
10. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504. (Pubitemid 32492970)
11. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, et al. Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005;43:360-9. 12. (Pubitemid 41078996)
12. Kojika M, Sato N, Hakozaki M, Suzuki Y, Takahasi G, Endo S, et al. [A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time]. Jpn J Antibiot 2005;58:452-7. 13.
13. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61. (Pubitemid 44684865)
14. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7. 15. (Pubitemid 44108605)
15. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? J Antimicrob Chemother 2007;59:285-91. (Pubitemid 47072068)
16. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-10. (Pubitemid 350067544)
17. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-40.
18. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83. (Pubitemid 34270031)
19. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Costeffectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-55. (Pubitemid 32411052)
20. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-8. 21.
21. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: Intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-7. 22. (Pubitemid 40023348)
22. van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-9. 23. (Pubitemid 44902883)
23. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007;44:357-63. (Pubitemid 46147617)
24. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9. 25.
25. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29. (Pubitemid 15250137)
26. Nicolau D, Quintiliani R, Nightingale CH. Once-daily aminoglycosides. Conn Med 1992;56:561-3. Erratum in: Conn Med 1992;56:694. (Pubitemid 23003752)
27. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, et al. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009;64:236-40.
28. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791-9. 29. (Pubitemid 38648413)
29. Fagon JY, Chastre J, Hance AJ, Guiguet M, Trouillet JL, Domart Y, et al. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in147 patients. Am Rev Respir Dis 1988;138:110-6. 30.
30. Wunderink RG, Woldenberg LS, Zeiss J, Day CM, Ciemins J, Lacher DA. The radiologic diagnosis of autopsy-proven ventilatorassociated pneumonia. Chest 1992;101:458-63.
31. Salata RA, Lederman MM, Shlaes DM, Jacobs MR, Eckstein E, Tweardy D, et al. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am Rev Respir Dis 1987;135:426-32. (Pubitemid 17012109)
32. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371-5. 33. (Pubitemid 32506601)
33. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676-82. (Pubitemid 36379567)
34. Garrard CS, A'Court CD. The diagnosis of pneumonia in the critically ill. Chest 1995;108 (2 Suppl):17S-25S. 35.
35. Abramson N, Melton B. Leukocytosis: Basics of clinical assessment. Am Fam Physician 2000;62:2053-60.
36. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903. (Pubitemid 34774654)
37. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989;139:877-84. (Pubitemid 19094308)
38. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655-62.
39. Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, et al. Incidence, risk, and prognostic factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990;142:523-8. (Pubitemid 20292709)
40. Spencer R. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996;15:281-5. (Pubitemid 26159687)